tbuckley/cabot-search huggingface dataset:
A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats
Authors: M SILVAANTONIALLI
Journal: Cardiovascular Research (2004)

Objective: Sexual dimorphism has been observed in arterial hypertension. Blood pressure levels are lower in female than in male spontaneously hypertensive rats (SHR). Angiotensin II (Ang II) plays a major role in the regulation of blood pressure. The aim of this study was to compare Ang IIvascular reactivity and AT1 and AT2 receptor gene expression in female and male SHR. Methods: SHR animals were divided into four groups: (I) male, (II) female in physiological estrus, (III) ovariectomized and (IV) ovariectomized treated with estrogen. Arterial blood pressure, AT1 and AT2 mRNA expression were determined. Ang II responses in aorta and mesenteric vessels were also evaluated. Results: In female SHR, aorta and mesenteric microvessels were hyporeactive to Ang II in comparison to male SHR. In ovariectomized females, Ang II vasoconstriction was similar to that of males. Estrogen treatment abolished this difference. The mRNA expression for AT1 was higher in aorta and mesenteric vessels from males than in females. In ovariectomized SHR, mRNA expression for AT1 was comparable to that of males. Treatment with estrogen reversed the over expression observed. Whereas AT2 gene expression did not differ, a lower ratio AT1/AT2 was found in female than in male vessels. A higher mRNA expression for AT1 was observed in kidney from male than in female. Ovariectomy resulted in up-regulation of this subtype receptor. Treatment with estrogen reversed the overexpression. AT2 gene expression was higher in kidney from female than male SHR. Ovariectomy reduced AT2 gene expression and estrogen treatment reversed the alteration observed in kidney. Conclusion: There is sexual dimorphism in vascular reactivity and in receptor gene expression to Ang II in SHR. We conclude that estrogen modulates AT1 and AT2 receptor gene expression and that this might explain at least partially the lower blood pressure observed in female SHR.
Abstract 3008: Intracoronary Compared with Intravenous Bolus Abciximab Application in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Coronary Intervention The randomized Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI)
Authors: Holger Thiele, Kathrin Schindler, Josef Friedenberger, Ingo Eitel, Georg Fürnau, Eigk Grebe, Dietmr Kivelitz, Gerhard Schuler
Journal: Circulation (2007)

Background Abciximab reduces major adverse cardiac events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Intracoronary bolus application of abciximab results in high local drug concentrations and may be more effective than standard intravenous bolus application for reduction of infarct size, no-reflow and improvement in perfusion. Methods Patients undergoing primary PCI were randomized to either intracoronary (n=77) or intravenous (n=77) bolus administration of abciximab with subsequent 12 hour intravenous infusion. Primary endpoint was infarct size and extent of microvascular obstruction assessed by delayed enhancement magnetic resonance. Secondary endpoints were ST-resolution at 90 minutes, Thrombolysis in Myocardial Infarction (TIMI)-flow and perfusion grade post PCI, and the occurrence of major adverse cardiac events within 30 days. Results The primary endpoint infarct size could be reduced by absolute 7% (17.7% i.c. versus 24.7% i.v., p=0.005). Similarly, the extent of microvascular obstruction was significantly smaller in i.c. patients in comparison to i.v. patients (p=0.02). Myocardial perfusion measured as early ST-segment resolution was significantly improved in i.c. patients with an absolute ST-resolution of 76±23% versus 64±31% (p=0.009). The TIMI flow after PCI was not different between treatment groups (p=0.51), but there was a trend towards an improved perfusion grade (p=0.12). There was a trend towards a higher major adverse cardiac event rate after intravenous versus intracoronary abciximab application (15.6% versus 5.2%, p=0.06; relative risk 3.00; 95% confidence intervals 0.94 –10.80). Conclusions: Intracoronary bolus administration of abciximab is superior to standard intravenous treatment with respect to infarct size, extent of microvascular obstruction, and perfusion in primary PCI. An adequately powered trial for major adverse cardiac event reduction is warranted.
THE STATE SOCIETIES.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Comment
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABSENCE OF VAGINA; UNILATERAL DEVELOPMENT OF INTERNAL GENITAL ORGANS; HEMATOMETRA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A VOLUNTARY NATIONAL EXAMINING BOARD.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Looking back to the future of radiology
Authors: A. A. Skolnick
Journal: JAMA (1995)

ONE HUNDRED YEARS ago, on November 8, working in his rather spartan laboratory in Würzburg, Germany, Wilhelm Conrad Röntgen (1845-1923) saw something just a few others had seen—but only he realized it was something new. Something<i>astonishingly</i>new. He noticed a glow coming from a phosphorescent screen not far from the cathode ray gas discharge tube he was using in one of his experiments. He traced the source of the invisible rays to the point where the cathode rays were striking the glass wall of the discharge tube. To his astonishment, the rays, unlike visible or ultraviolet light, readily penetrated many opaque objects—including the flesh of his hand, revealing an uncanny shadowy image of his bones. Unlike cathode rays, the mysterious new rays would not be bent by either magnetic or electric fields. Röntgen had discovered x-rays—and begun the transition from classical to modern physics. That discovery was the beginning
British Journal of Psychiatry, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TREATMENT OF PULMONARY TUBERCULOSIS WITH ANTITUBERCULOUS SERUM.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Got Insurance?
Authors: Bridget M. Kuehn
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of sequential administration of S-1 and cisplatin (CDDP) in patients with metastatic gastric cancer (MGC)
Authors: E. Baba, K. Tsukasa, H. Ariyama, T. Esaki, K. Sakai, H. Fujishima, K. Mitsugi, H. Kusaba, K. Akashi, S. Nakano
Journal: Journal of Clinical Oncology (2008)

15665 Background: The combination of 5-FU and CDDP has been shown to be active against metastatic gastric cancer, and a great synergy has been reported in vivo and in vitro when 5-FU precedes CDDP. We assessed the sequential combination of S-1 (Tegafur, oxonic acid, CDHP) followed by CDDP in MGC. Methods: In order to determine effectiveness and tolerability, we conducted a phase II trial applying oral administration of S-1 (80mg/m2) for 21 days and CDDP (70mg/m2) on day 22 every 35 days, of which doses were recommended by our previous phase I study. Pts with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, performance status ECOG less than 3, and adequate organ functions were eligible. Planned sample size was 50. Results: Twenty seven pts were evaluable for toxicity and 19 pts were evaluable for response. The response rate at this point was 42.1%. Hematological toxicity with NCICTC grade 3/4 was neutropenia (22.2%), anemia (14.8%) and thrombocytopenia (7.4%). Major non-hematological toxicities included anorexia and diarrhea. No treatment related death has been observed. Conclusions: This sequential S-1 and CDDP administration is feasible and tolerated with promising activity. Further analysis will be presented in the meeting. No significant financial relationships to disclose.
Lipid Research Clinics Program-Reply
Authors: Basil M. Rifkind
Journal: JAMA (1984)

<h3>In Reply.—</h3> Because prothrombin times and serum ferritin levels were not measured in the LRC-CPPT, a beneficial effect of anticoagulation or depletion of iron stores in the cholestyramine group cannot be completely ruled out. Attribution of the benefits of cholestyramine therapy to cholesterol lowering is based on the several lines of evidence set out in the second of the two<i>JAMA</i>articles presenting the results of the trial and in the large amount of prior information relating blood cholesterol levels to CHD. No such body of epidemiologic and clinical trial evidence exists linking iron or vitamin K absorption to CHD. The suggestion that iatrogenic anticoagulation might have contributed to the six accidental deaths in the cholestyramine group is not borne out by the autopsy evidence. All of the five men on whom autopsies were performed had sustained injuries sufficient to account for their deaths in the presence of normal clotting
Radiologic Examination of the Orohypopharynx and Esophagus.
Journal: Annals of Internal Medicine (1978)

such as De-Ritis ratio and the TGR.These are used descriptively without any detailed discussion of the origin of the enzyme, its specificity, or even its name: all enzymes are referred to by initialsfor example, GOT, CHE, GLDH.The assumption of familiarity with these abbreviations may be correct for the continental reader, but is likely to be received with dismay in this English translation aimed at the British and American markets.The book should prove useful to a British physician wanting to assess the value of laparoscopy.Its price may deter others from purchasing it even for their library.
Abstracts
Journal: Annals of the Rheumatic Diseases (1969)

The acute rheumatic diseases of childhood are known to be associated with a rise in the serum y-globulin level, but the relative parts played by the individual immuno- globulin fractions is unclear, although several studies have been reported.At Zahalon Government Hospital, Jaffa, and Tel Aviv University Medical School, Israel, the authors carried out serial determinations of the serum IgG, IgA, and IgM levels in 24 children aged 6 to 12 years admitted to hospital with acute rheumatism.Four had polyarthritis only, ten carditis only, nine carditis with polyarthritis, and one carditis and chorea.All were treated with salicylates and fifteen also with prednisone (2 mg./kg.body weight daily for about 3 weeks).Blood samples were taken within the first week and at intervals of 7 to 10 days throughout each child's stay in hospital.Immunoglobulin estimations were performed conven- tionally by the method of Fahey, using commercial standards and antibody-containing diffusion plates.Ten healthy children of the same age range served as controls.The. mean values (for 20 patients) of all three immunoglobulins were significantly higher (P < 0-01) in the acute stage than at 7 to 10 days after the termination of treatment, when the disease was considered to be inactive, but in comparison with the control group the increase in IgM level was not significant (P < 0-1).The mean levels of IgG and IgA rose in parallel during the first 2 weeks of the illness and then fell, again in parallel, to reach the normal (control) range at about the 6th week.The mean IgM level fell during the course of the illness but remained within the control range throughout.The authors point out that the similarity of timing between the changes in serum IgG and IgA levels is difficult to understand, as the rate of catabolism for IgA is much higher than that for IgG though their rates of synthesis are much the same.Various possible explanations of this apparent discrepancy are discussed, including a change in distribution of IgA between glandular secretions and the blood such as has been postulated in rheumatoid arthritis, and it is suggested that a better understanding of serum IgA changes (which, unlike IgG changes, would not be expected to follow simple bacterial infection) may be helpful in explaining the nature of rheumatic fever.
A NEW DISEASE OF THE BREAST
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Practical Observations on Supporting the Perinaeum
Authors: G. Hewitt
Journal: BMJ (1861)

Is it possible once and for all to settle the vexed question of the proper treatment of the perinreum in labour ?It is very certain that the formation of some definitive conclusions on the subject would be acceptable to those-and they are manv-who are engaged in the arduous duties of obstetric practice, and to whom a divided opinion among " the best authorities" on a matter ,of such every-day occur- rence as the manag,ement of a natural labour is per- plexing and unsatisfactory in the extreme.The following remarks may or may not assist in the formatiorn of such definitive conclusions; they * Allusion is here more particularly made to a very able pakper by Dr. Leishmaui, in the Gaesgow Medical Journtal for Janiuary 1860.
A first report of the Department of Defense external civilian peer review of medical care
Authors: W. Mayer
Journal: JAMA (1988)

In mid-1985, the Department of Defense announced a plan for an external civilian peer review of selected medical and surgical cases in military hospitals. A medical advisory panel consisting of practicing clinical representatives from nine medical specialty societies helped develop written criteria and standards for specific surgical and medical cases. Abstracted data were compared with computer algorithms created from the medical standards and criteria. Those cases failing the review criteria were reviewed by a physician peer review panel. The sampled medical records represented approximately 7% to 8% of the total hospital discharges. Less than 1% of the overall sampled cases were in non-compliance with stated standards. The highest rate of noncompliance was for cases of diabetic ketoacidosis. The most frequent noncompliance event was hysterectomy. Although comparisons are not available, the quality of care among selected cases, as measured by compliance with civilian physician specialty group—endorsed standards, appeared high. (<i>JAMA</i>1988;260:2690-2693)